Liaoning Boao Biological Pharmaceutical Co.,Ltd
Liaoning Boao Biological Pharmaceutical Co.,Ltd is a Chinese biopharmaceutical enterprise founded in 2010. The company is located in the Chinese Medicine Capital area of Liaoning, in Shenben New City, Benxi, China. Its location is described as being approximately 20 kilometers from Shenyang Taoxian Airport, with convenient access to high-speed rail and expressways, which supports efficient logistics and distribution activities. The company’s core focus lies in research and development, and it specializes in the production of insulin products and APIs, integrating modern biological science and technology. This positions Liaoning Boao Biological Pharmaceutical Co.,Ltd as a notable player in the biopharmaceutical sector within Liaoning Province.
According to the information provided, the enterprise has formal production capacity and has established dedicated facilities that support its pharmaceutical manufacturing operations. The registered capital is listed as 50,000,000 Yuan, and the company covers a total area of 35,000 square meters. The infrastructure includes active pharmaceutical ingredient (API) production facilities, cassette bottle injection workshops, a solvent recovery workshop, integrated office buildings, and both research and development laboratories. These facilities collectively occupy a substantial footprint, enabling a combination of manufacturing, quality control, research activity, and administrative operations.
The company’s organizational framework appears to include a workforce of 58 staff members, with a mix of educational backgrounds that include doctors, postgraduates, and bachelor-degree professionals. Specifically, the profile notes the presence of 2 doctors, 4 postgraduates, and 28 holders of bachelor’s degrees. Such a composition suggests a research-oriented environment that supports ongoing development in insulin APIs and related injection products, aligning with the broader trend of combining scientific research with scalable manufacturing capabilities in the biopharmaceutical industry.
Liaoning Boao Biological Pharmaceutical Co.,Ltd emphasizes its position as a leading enterprise in Liaoning Province, indicating a recognized role in the regional biopharmaceutical landscape. The company’s growth over the years reflects an emphasis on independent innovation and the development of multiple insulin-related products. The narrative indicates progress through collaboration and knowledge transfer from domestic and overseas sources, pointing to a strategy that leverages external expertise to enhance internal capabilities.
From a logistical and supply chain perspective, the stated proximity to an international airport, as well as the accessibility to high-speed rail and expressways, suggests favorable conditions for the movement of materials, finished products, and potentially sensitive pharmaceutical items. While the available information does not detail specific freight forwarding or cold-chain logistics capabilities, the existing infrastructure and location imply a potential for efficient coordination of supply chain activities in support of pharmaceutical manufacturing and distribution.
Given the information available, Liaoning Boao Biological Pharmaceutical Co.,Ltd presents as a fully integrated biopharmaceutical enterprise with emphasis on insulin APIs and injections, supported by substantial production facilities, a dedicated laboratory environment, and a strategic geographic position. The described assets and capabilities indicate a coherent business model aimed at sustaining research-driven development while maintaining scale-ready manufacturing operations within Liaoning Province.
